A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...
Feb 26 (Reuters) - Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment ...
Feb 26 () - Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss pill, ...
Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.
Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.
Patients may have trouble finding two different types of insulin products made by Eli Lilly. The company said it's experiencing a shortage of its 10 mL vials of Humalog and Insulin Lispro Injection ...
26d
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...
The stock looks unstoppable.
Eli Lilly isn't a one-trick pony.
The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its ...
Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results